Reliance Life Sciences Pvt Ltd has received a licence from the Indian Institute of Technology Kanpur for a gene therapy method that has the potential to treat a variety of genetic eye ailments. Reliance Life Sciences will further develop the gene treatment technology from IIT Kanpur into a native product. The science of molecular medicine has recently seen the emergence of gene therapy employing viral vectors as a powerful tool.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
The patented technology was created by Jayandharan Giridhara Rao and Shubham Maurya from the Department of Biological Sciences and Bioengineering (BSBE), IIT Kanpur, to treat a genetic illness by altering an organism’s gene.
According to IIT Kanpur, this is the first instance in which a gene therapy-related technology has been created and given to a business in India. To meet unmet therapeutic requirements, Reliance Life Sciences is creating a number of different gene treatments. Also, the company is working on a variety of mRNA products and vaccines for both human and animal health.
Human gene therapy aims to change a gene’s expression or the biological characteristics of living cells for therapeutic purposes. Gene therapy is a method for treating or curing disease by changing a person’s DNA. Gene treatments can function in a variety of ways:
Products utilising gene therapy are being investigated for the treatment of diseases like cancer, genetic disorders, and infectious diseases.
You may also read this:
From the sprawling plains of the Midwest to the sun-kissed shores of the Pacific, the…
The Indian political landscape has lost a seasoned leader with the passing of V. Srinivas…
The Badminton World Federation (BWF) has announced that India will host the prestigious 2025 BWF…
In the mosaic of American cities, certain urban centers stand out as bastions of liberal…
In a remarkable achievement, ICICI Bank has etched its name among India's top five companies…
The Government of India has introduced a Floating Rate Bond (FRB) maturing in 2034, with…